Meta-analysis of Associations between the MDM2-T309G Polymorphism and Prostate Cancer Risk

The mouse double minute 2 (MDM2) gene plays a key role in the p53 pathway, and the SNP 309T/G single-nucleotide polymorphism in the promoter region of MDM2 has been shown to be associated with increased risk of cancer. However, no consistent results were found concerning the relationships between the polymorphism and prostate cancer risk. This meta-analysis, covering 4 independent case-control studies, was conducted to better understand the association between MDM2-SNP T309G and prostate cancer risk focusing on overall and subgroup aspects. The analysis revealed, no matter what kind of genetic model was used, no significant association between MDM2-SNP T309G and prostate cancer risk in overall analysis (GT/TT: OR = 0.84, 95% CI = 0.60-1.19; GG/TT: OR = 0.69, 95% CI = 0.43-1.11; dominant model: OR = 0.81, 95% CI= 0.58-1.13; recessive model: OR = 1.23, 95% CI = 0.95-1.59). In subgroup analysis, the polymorphism seemed more likely to be a protective factor in Europeans (GG/TT: OR = 0.52, 95% CI = 0.31-0.87; recessive model: OR = 0.58, 95% CI = 0.36-0.95) than in Asian populations, and a protective effect of the polymorphism was also seen in hospital-based studies in all models (GT/TT: OR = 0.74, 95% CI = 0.57-0.97; GG/TT: OR = 0.55, 95% CI = 0.38-0.79; dominant model: OR = 0.69, 95% CI = 0.54-0.89; recessive model: OR = 0.70, 95% CI = 0.51-0.97). However, more primary studies with a larger number of samples are required to confirm our findings.